Free Trial
→ The warning signs most investors see too late (From Weiss Ratings) (Ad)tc pixel
NASDAQ:INDV

Indivior Q2 2026 Earnings Results & Report

Indivior logo
$28.21 +0.06 (+0.21%)
As of 11/4/2026

Indivior reported Q2 2026 earnings on June 30, 2026. The company reported EPS of $5.75, while revenue was $343 million.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
Before Market Opens

Indivior EPS Results

Actual EPS
$5.75
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
7 of last 8 quarters

Indivior Revenue Results

Actual Revenue
$343 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Indivior Q2 2026 Earnings FAQ

Indivior (NASDAQ:INDV) reported earnings of $5.75 per share for Q2 2026. The report was announced on Tuesday, June 30, 2026.

Indivior reported revenue of $343 million for Q2 2026.

Indivior Earnings Headlines

Analyzing Indivior (INDV) and Its Rivals
November 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31183229
Indivior Pharmaceuticals (INDV) Shareholders Back Merger After Record Third Quarter
October 30, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/indivior-pharmaceuticals-indv-shareholders-back-051526361.html
This is likely to EXPLODE
Dr. Martin D. Weiss, founder of Weiss Ratings and a two-time Congressional witness on financial institution risk, is warning of a looming $3 trillion threat in today's financial system. He says the same ratings agency practices that preceded the 2008 crisis are repeating themselves, while regulators stay quiet about the risks.tc pixel
November 14 at 1:00 AM  |  Weiss Ratings (Ad)
(INDV) Indivior Expects 2026 Net Revenue Range $1.30B to $1.37B, vs. FactSet Est of $1.33B
October 29, 2026  |  marketscreener.comM
Indivior Reports Third Quarter 2026 Financial Results
October 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/29/3391124/0/en/indivior-reports-third-quarter-2026-financial-results.html
Indivior to Report Third Quarter 2026 Financial Results
October 19, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/19/3383430/0/en/indivior-to-report-third-quarter-2026-financial-results.html
See More Indivior Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Indivior? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Indivior and other key companies, straight to your email.

About Indivior

Indivior (NASDAQ:INDV) is a specialty pharmaceutical company focused on developing and providing treatments for substance use disorders and serious mental illness. Its products include medicines for opioid use disorder, such as Sublocade, a long-acting injectable form of buprenorphine, and Suboxone, a buprenorphine-and-naloxone treatment.

The company also markets Opvee, a nasal spray used to reverse opioid overdose, and Perseris, a long-acting injectable treatment for schizophrenia. Indivior develops additional therapies through its research and development programs.

Indivior was formed in 2014 when Reckitt Benckiser separated its pharmaceutical business. It serves patients and healthcare providers in the United States and other markets, with a substantial focus on the U.S. addiction-treatment market.

View Indivior Profile
Earnings Tools